DETECT V/CHEVENDO - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

被引：2
|
作者：
Krause, S.
Friedl, T.
Fehm, T.
Romashova, T.
Fasching, P. A.
Schneeweiss, A.
Mueller, V.
Taran, F-A
Polasik, A.
Tzschaschel, M.
De Gregorio, A.
Meier-Stiegen, F.
Janni, W.
Huober, J.
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
[3] Univ Hosp Erlangen, Erlangen, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[7] Univ Hosp Tubingen, Tubingen, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-07-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-01
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer
    Iorfida, Monica
    Bagnardi, Vincenzo
    Balduzzi, Alessandra
    Dellapasqua, Silvia
    Cardillo, Anna
    Luini, Alberto
    Intra, Mattia
    Minchella, Ida
    Veronesi, Paolo
    Viale, Giuseppe
    Goldhirsch, Aron
    Colleoni, Marco
    BREAST, 2010, 19 (02): : 128 - 132
  • [22] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Carlos Acevedo-Gadea
    Christos Hatzis
    Gina Chung
    Neal Fishbach
    Kimberly Lezon-Geyda
    Daniel Zelterman
    Michael P. DiGiovanna
    Lyndsay Harris
    Maysa M. Abu-Khalaf
    Breast Cancer Research and Treatment, 2015, 150 : 157 - 167
  • [23] Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
    Okemoto, Dai
    Yamaguchi, Toshifumi
    Yamaguchi, Mariko
    Kadono, Toru
    Yukami, Hiroki
    Fakhrejahani, Elham
    Nishikawa, Hiroki
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 1001 - 1007
  • [24] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [25] Outcomes of Patients With HER2-Positive Breast Cancer Metastatic to Brain Treated With HER2-Targeted Systemic Therapy and Stereotactic Radiosurgery
    Shumway, J. W.
    Torras, M.
    Hayes, K. Reeder
    Jolly, T.
    Dees, E. C.
    Ray, E. M.
    Carey, L. A.
    Shen, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E580 - E580
  • [26] Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
    Acevedo-Gadea, Carlos
    Hatzis, Christos
    Chung, Gina
    Fishbach, Neal
    Lezon-Geyda, Kimberly
    Zelterman, Daniel
    DiGiovanna, Michael P.
    Harris, Lyndsay
    Abu-Khalaf, Maysa M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (01) : 157 - 167
  • [27] Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
    Montemurro, Filippo
    Rossi, Valentina
    Rocca, Maria Cossu
    Martinello, Rossella
    Verri, Elena
    Redana, Stefania
    Adamoli, Laura
    Valabrega, Giorgio
    Sapino, Anna
    Aglietta, Massimo
    Viale, Giuseppe
    Goldhirsch, Aron
    Nole, Franco
    CANCER, 2012, 118 (01) : 17 - 26
  • [28] Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
    Berghoff, A.
    Bartsch, R.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rudas, M.
    Pluschnig, U.
    Wiltschke, C.
    Gnant, M.
    Steger, G. G.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
    Ventura, Ignacio
    Salcedo, Nerea Pinilla
    Perez-Bermejo, Marcelino
    Perez-Murillo, Javier
    Tejeda-Adell, Manuel
    Tomas-Aguirre, Francisco
    Legidos-Garcia, Maria Ester
    Murillo-Llorente, Maria Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [30] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
12345